Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Placebo-controlled
100%
Phase II Study
100%
Randomized Double-blind
100%
Novel Antibodies
100%
Advanced Colorectal Cancer
100%
Antibody Treatment
100%
MABp1
100%
Placebo
36%
One Dose
27%
Placebo Groups
27%
Disease-related
9%
Serious Adverse Events
9%
Poor Prognosis
9%
Interleukin-1β
9%
Relative Risk
9%
Clinical Performance
9%
Anemia
9%
Adverse Events
9%
Weight Loss
9%
Systemic Inflammation
9%
Antitumor Activity
9%
Modified Intention-to-treat
9%
New Primary
9%
Response System
9%
Interactive Web Response
9%
Anorexia
9%
Intravenous Infusion
9%
Alkaline Phosphatase
9%
Aspartate Aminotransferase
9%
Metastatic Disease
9%
Oxaliplatin
9%
Baseline Measurements
9%
Resectable Disease
9%
Randomized Phase III Trial
9%
Eastern Cooperative Oncology Group Performance Status (ECOG PS)
9%
Irinotecan
9%
Body Stability
9%
New Standards
9%
Lean Body Mass
9%
Performance Status Score
9%
Medicine and Dentistry
Placebo
100%
Colorectal Cancer
100%
Disease
22%
Adverse Event
22%
Intention-to-Treat Analysis
11%
Oncology
11%
Symptom
11%
Intravenous Drug Administration
11%
Anemia
11%
Interleukin 1
11%
Antineoplastic Activity
11%
Anorexia
11%
Aspartate Aminotransferase
11%
Alkaline Phosphatase
11%
Oxaliplatin
11%
Pain (Symptom)
11%
Irinotecan
11%
Lean Body Weight
11%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Cancer
100%
Placebo
100%
Disease
22%
Symptom
22%
Adverse Event
22%
Alkaline Phosphatase
11%
Inflammation
11%
Interleukin 1
11%
Antitumor Activity
11%
Anorexia
11%
Aspartate Aminotransferase
11%
Anemia
11%
Oxaliplatin
11%
Irinotecan
11%